Home Cart Sign in  
Chemical Structure| 2134675-36-6 Chemical Structure| 2134675-36-6

Structure of Ziftomenib
CAS No.: 2134675-36-6

Chemical Structure| 2134675-36-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor that exhibits anti-tumor activity, particularly in MLL fusion-related leukemias, showing significant application potential.

Synonyms: KO-539

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ziftomenib

CAS No. :2134675-36-6
Formula : C33H42F3N9O2S2
M.W : 717.87
SMILES Code : N#CC(N1C[C@@H](N2CCN(S(=O)(C)=O)CC2)C)=CC3=C1C=CC(CN4CCC(NC5=C(C=C(CC(F)(F)F)S6)C6=NC(NC)=N5)CC4)=C3C
Synonyms :
KO-539
MDL No. :N/A

Safety of Ziftomenib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Ziftomenib

epigenetics

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06440135 Acute Myeloid Leukemia|Acute M... More >>yeloid Leukemia in Remission|NPM1 Mutation|KMT2A Rearrangement Less << PHASE1 RECRUITING 2027-09-01 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States Less <<
NCT04067336 Advanced Malignant Neoplasm|Ac... More >>ute Myeloid Leukemia|Mixed Lineage Leukemia|Mixed Lineage Acute Leukemia|Acute Leukemia of Ambiguous Lineage|Mixed Phenotype Acute Leukemia Less << PHASE1|PHASE2 RECRUITING 2025-09-30 Banner MD Anderson Cancer Cent... More >>er, Gilbert, Arizona, 85234, United States|Mayo Clinic, Phoenix, Arizona, 85054, United States|University of Southern California, Los Angeles, California, 90033, United States|UCLA Bowyer Oncology Center, Los Angeles, California, 90095, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Northwestern University, Chicago, Illinois, 60611, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, 46202, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan Hospitals, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, 07601, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14203, United States|Weill Cornell Medical College - NY Presbyterian Hospital, New York, New York, 10021, United States|The Mount Sinai Hospital, New York, New York, 10029, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Oklahoma University Health - Stephenson Cancer Center, Oklahoma City, Oklahoma, 73117, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center, Dallas, Texas, 75390, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|UZ Brussel, Jette, 1090, Belgium|AZ Delta - Campus Rumbeke, Roeselare, 8800, Belgium|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Hopital Maisonneuve-Rosemont, Montréal, Quebec, H1T 2M4, Canada|Hopital de l'Enfant-Jesus - Centre Integre en Cancerologie du CHU de Quebec - Universite Laval, Québec, Quebec, G1J 1Z4, Canada|CHU de Quebec - Universite Laval, Hopital de l'Enfant - Jesus, Québec, Quebec, G1S 4L8, Canada|CHU de Lille, Lille, 59037, France|CHU de Nantes, Nantes, 44093, France|Hopital Saint Louis, Paris, 75475, France|Magendie Hopital Haut-Leveque, Pessac, 33600, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69310, France|Institut Gustave Roussy, Villejuif, 94800, France|Charitè-Campus Benjamin Franklin, Berlin, 12203, Germany|University Medicine Greifswald, Greifswald, 17475, Germany|Medizinische Hochsschule Hannover, Hannover, Germany|Johannes Gutenberg - University Mainz, Mainz, 55131, Germany|Institute of Hematology and Medical Oncology "L. and A. Seragnoli", Bologna, 40138, Italy|IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, 47014, Italy|UO Ematologia Ospedale di Ravenna, Ravenna, 48121, Italy|Institution Fondazione Policlinico Tor Vergata, Roma, Italy|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Universitat de Barcelona, Barcelona, 08035, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Hospital Universitario Central de Asturias, Oviedo, 33011, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|St. George's Hospital, London, SW17 0QT, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.97mL

1.39mL

0.70mL

13.93mL

2.79mL

1.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories